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Summary
The etiology of human tumors often involves chromosomal translocations. Models that emulate translocations are essential
to understanding the determinants of frank malignancy, those dictating the restriction of translocations to specific lineages,
and as a basis for development of rational therapeutic methods. We demonstrate that developmentally regulated Cre-
loxP-mediated interchromosomal recombination between the Mll gene, whose human counterpart is involved in a spectrum
of leukemias, and the Enl gene creates reciprocal chromosomal translocations that cause myeloid tumors. There is a rapid
onset and high penetrance of leukemogenesis in these translocator mice, and high proportions of cells carrying chromo-
somal translocations can be found in bone marrow as early as 12 days after birth. This de novo strategy is a direct
recapitulation of naturally occurring human cancer-associated translocations.
Introduction be found in myeloid and lymphoid leukemias (Ayton and Cleary,
2001).
Mouse models which mimic the effects of chromosomalThe etiology of tumors often involves chromosomal transloca-
tions in hematopoietic malignancies, sarcomas, and epithelial translocations, or which recapitulate these events, are essential
to understanding the determinants of frank malignancy andtumors, and these can either activate protooncogenes or create
novel fusion genes that function in tumorigenesis (Rabbitts, those dictating the restriction of translocations to specific lin-
eages. In addition, with advancement of efforts to devise new1994). These translocation products act at various levels in
afflicted cells, although the translocation genes always encode reagents which can interfere with protein function, mouse mod-
els of human cancer are crucial to developing and testing theseintracellular proteins located in either the cytoplasm or nuclei.
The recurrent chromosomal translocations in hematopoietic rationally devised therapeutic approaches prior to application
in patients. Finally, mouse models of human cancer will bemalignancies and in sarcomas generally display a tropism in
respect of the cell type in which they are found, for instance, the needed for in vivo testing of new compounds, which may have
promising biochemical properties, in order to accelerate theMLL gene fusion subtypes being restricted to either lymphoid or
myeloid malignancies (Downing and Shannon, 2002; Look, translation of these into clinical use. Mouse cancer models in-
volving chromosomal translocation genes have been either1997; Rowley, 1998). The MLL gene is a frequent site of chromo-
somal translocations in human leukemias (Corral et al., 1993; gain-of-function transgenic models (Adams et al., 1999; Pan-
dolfi, 1998), retroviral transduction models, or translocationDjabali et al., 1992; Domer et al., 1993; Gu et al., 1992; Thirman
et al., 1993; Tkachuk et al., 1992), affecting over 30 different mimics in which a gene fusion is created by homologous recom-
bination into an endogenous target gene using embryonic stemchromosomes and resulting in many leukemia-associated MLL-
gene fusions (Ayton and Cleary, 2001; Collins and Rabbitts, cells (ES cells) (Corral et al., 1996). For instance, the conse-
quences of MLL-associated translocations have been modeled2002). Different fusions distinguish distinct leukemias, for in-
stance, the MLL-AF9 fusion is almost exclusively in myeloid in mice using retroviral transduction of bone marrow progenitors
(Lavau et al., 1997; Schulte et al., 2002; Slany et al., 1998) orleukemias while MLL-AF4 is confined to B lymphoid leukemias
(Gu et al., 1992; Rowley, 1998). Others, such as MLL-ENL, can by homologous recombination knockin of fusion genes (Corral
S I G N I F I C A N C E
Mouse models of human cancers are important for understanding determinants of overt disease and for “preclinical” development
of rational therapeutic strategies. Chromosomal translocations underlie many human leukemias, sarcomas, and epithelial tumors.
There are several approaches modeling the effects of chromosomal translocations in mice but none fully recapitulate human
translocations and none generate both reciprocal products. We describe a system by which chromosomal translocations occur de
novo during mouse development and cause tumors carrying both reciprocal translocated chromosomes. This de novo model mirrors
the situation found in humans and provides the framework for design of any chromosomal translocation in mice. In this model, we
have studied the Mll gene fusion with Enl and found a high penetrance and rapid onset of tumors.
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Figure 1. Targeting and recombination strategy
for Mll and Enl genes
LoxP recombination sites were introduced into
the mouse Mll (Collins et al., 2000) and Enl genes
using gene targeting in ES cells. The targeted
cells were injected into blastocysts, and chi-
maeric mice that carried the modified alleles
were derived. These were bred to obtain germ-
line transmission and subsequently interbred with
each other and with a line in which Cre recombi-
nase is expressed from the Lmo2 gene.
A: Map of the mouse Mll gene indicating three
exons of the gene and the BglII restriction site at
which was cloned a loxP cassette with a hygro-
mycin-selectable marker (Johnson et al., 1995).
The pMll-loxP-hygro targeting vector is shown in
the middle line and the organization of the tar-
geted allele in the bottom line, showing that the
loxP site is downstream of exon 10 of Mll.
B: The mouse Enl gene indicating exon 2 and the
SphI restriction site at which was cloned a loxP
cassette with a puromycin-selectable marker
(Linnell et al., 2001). The top line is the germline
map, the middle is the pEnl-loxP-puro targeting
vector, and the bottom is the structure of the
targeted allele.
C: Cells or mice with both the Mll (chromosome
9) and Enl (chromosome 17) loxP alleles can un-
dergo Cre-dependent interchromosomal recip-
rocal translocation. The derivative t(9.17) and
t(17;9) are diagrammatically shown in the 3rd and
4th lines, respectively.
D and E: To verify the ability of the Mll and Enl
genes to participate in interchromosomal trans-
locations, Cre recombinase was transiently ex-
pressed in ES cell lines carrying both loxP alleles.
Genomic DNA or mRNA were prepared for ge-
nomic PCR (D) or RT-PCR (E) with Mll- and Enl-
specific primers. For the genomic PCR, primers
MG1 (from Mll) and EG1 (from Enl) allowed am-
plification of a 430 bp fragment, the sequence
of which comprised the junction of the Mll chro-
mosome, the loxP site, and the Enl chromosome
(D). RT-PCR was carried out with RNA from the
cells using an Mll exon 10 primer (MR1) and an
Enl exon 2 primer (ER1) to determine if the Mll-
Enl fusion mRNA could be detected. A 390 bp
PCR was detected and sequenced, showing the
in-frame fusion of Mll and Enl sequences (E).
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Figure 2. Myeloid leukemia development depends on Cre expression
A cohort of animals (n  21) was generated which had the genotype Mll-loxP; Enl-loxP; Cre (Mll;Enl;Cre) and a control group (n  15) with Mll-loxP; Enl-
loxP alleles (Mll; Enl) but lacking the Lmo2-Cre gene. Survival curves are shown in A. Mice were carefully observed from birth and post-mortem examination
carried out at first signs of ill health. Biopsies of tissues were taken, together with blood smears. Smears were stained with MGG stain, and photographs
show the presence of a large number of leukocytes (B, X10) and high power shows immature and mature myeloid forms (B, X100). Fluorescence activated
cell sorter analysis of surface phenotype is shown in C. Spleen (spl) and bone marrow (BM) cells were prepared from Mll-loxP; Enl-loxP; Cre or from Mll-loxP;
Enl-loxP mice and stained with fluorescent antibodies as indicated. Antibodies used were FITC-Gr-1 (Ly-6G) plus PE-Mac-1 (CD11b), FITC-CD8a (Ly2), or
FITC-B220 (CD45R) plus PE-CD4 (L3T4). The myeloid cells from the Mll-loxP; Enl-loxP; Cre mice lack Sca-1 and c-Kit expression. In addition, a cell line (CL)
established from a Mll-loxP; Enl-loxP; Cre mouse (designated 1) was analyzed with FITC-Gr-1 plus PE-Mac-1 and compared with a cell line established from
the Mll-AF9 knockin mice (Corral et al., 1996).
et al., 1996; Dobson et al., 1999, 2000). In the knockin approach, targeted gene is expressed, for instance as found for the Mll-
AF9 knockin fusion (Corral et al., 1996). In addition, dominant,homologous recombination was used to introduce fusion onco-
genes into mice via embryonic stem cells. In this way, a mouse embryonic lethal effects of knockin alleles have been observed
(Okuda et al., 1998; Yergeau et al., 1997). These can be over-model of the human MLL-AF9 gene fusion was made in which
knockin mice were found to develop an acute myeloid malig- come by creating conditional knockin alleles such as the Aml1-
Eto example, which circumvents the embryonic lethal effectsnancy similar to that found in human patients with the chromo-
somal translocation t(9;11) (Corral et al., 1996; Dobson et al., of the fusion and causes AML to arise in mice (Higuchi et al.,
2002).1999). While the knockin approach is a close mimic of natural
chromosomal translocations, it is limited by the fact that the The most ideal concept is the de novo creation of chromo-
somal translocation in mice, which could potentially be achievedhomologous recombination event generates a knockin of one
allele which is subsequently transferred to all cells of the mouse. by in vivo recombination systems, such as the Cre-loxP system
(Smith et al., 1995; van Deursen et al., 1995). This approachThus the fusion gene will be expressed in all sites where the
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Figure 3. Histology of tissues from Mll-loxP-Enl-loxP leukemic mice
Haematoxylin- and eosin-stained sections of tissues from leukemic mice (Mll; Enl; Cre) were compared with control tissue from an Mll-Enl only, age-matched
mouse (wt). All organs examined were heavily infiltrated with myeloid cells. The liver shows perivascular deposits of myeloid cells and heavy infiltration of
the tissue, and similarly, deposits of leukemic cells were found in kidney between the glomerili. The blood vessel in the liver sections illustrate the high
number of leukocytes circulating in these mice, compared with a vessel in the control liver. The spleen shows loss of normal architecture, with myeloid cells
in abundance.
would be the nearest to a direct recapitulation of the de novo and high penetrance of leukemogenesis. This approach is a
occurrence of human cancer-associated chromosomal translo- direct recapitulation of human cancer-associated transloca-
cations. The Cre-loxP recombination system has been shown tions, formally showing that these cause cancers, which are
to facilitate de novo chromosomal translocations in mice (Buch- most likely clonal in origin. The strategy can be used to generate
holz et al., 2000; Collins et al., 2000) but no tumor incidence de novo reciprocal translocations that effectively recapitulate
was reported in these initial translocator mice, possibly due to any naturally occurring translocation in human cancers.
the restricted expression characteristics of the Cre recombinase
in these first generation models. We have established a line of Results
mice in which Cre recombinase is expressed via the hematopoi-
etic Lmo2 gene (Warren et al., 1994) and where loxP sites have Interchromosomal translocations between mouse Mll
been engineered into Mll and Enl loci. We demonstrate that and Enl genes
Cre-loxP-mediated interchromosomal recombination between The strategy used to generate chromosomal translocations was
the Mll and Enl genes creates reciprocal chromosomal translo- to introduce loxP sites into equivalent introns of the Mll and Enl
cations, which rapidly cause myeloid tumors with rapid onset genes to those involved in human leukemia translocations, using
homologous recombination in ES cells. The ES cells were used
to make mice carrying these genetic alterations and inter-bred
with Cre-expressing mice. We have previously described the
Table 1. Differential leukocyte count from blood smears of Mll-Enl-Cre mouse mouse Mll-loxP gene in ES cells, at a site corresponding to
Leukocytes (n  438) Myeloid cells (n  417) human translocations (Figure 1A) (Collins et al., 2000). Similarly,
a loxP site was engineered into an Enl gene intron, upstreamNeutrophils 275 (63%) 275 (66%)
Nonsegmented forms 31 (7%) 31 (7%) of exon 2 (Figure 1B). Somatic recombination between these
Monocytes 20 (4%) 20 (5%) sites should create a mouse fusion gene equivalent to the MLL-
Myelocytes 61 (14%) 61 (15%)
ENL fusion found in human leukemias with t(11;19) (Ayton andMyeloblasts 30 (7%) 30 (7%)
Cleary, 2001).Lymphocytes 21 (5%)
Initial tests were performed to confirm that translocationsBlood films were prepared at time of sacrifice and stained with May-Grun-
were possible between mouse chromosomes 9 and 17 (Mll andwald-Giemsa (MGG) stain. Morphology of leukocytes was microscopically
examined and assessment of cell type and diagnosis made by reference Enl chromosomes, respectively) by expressing Cre protein in
to published criteria (Bain, 1993; Kogan et al., 2002). Data shown are for a ES cells carrying both the Mll and Enl loxP alleles. After transient
typical distribution profile of cell types. expression of Cre protein, genomic DNA and mRNA were iso-
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Figure 4. Reciprocal chromosomal translocations occur in Mll-loxP;Enl-loxP; Cre mice
A: DNA was prepared from tissues of mice at time of death and filter hybridization analysis carried out using probes able to detect DNA fragments from
putative chromosomal translocations. An example (specimen 1) is shown in A. Genomic DNAs from the indicated sources were digested with SphI, fragments
separated on 0.8% agarose, transferred to nylon membranes and hybridized with an Mll 5 probe (Collins et al., 2000) (left hand panel), digested with KpnI
and hybridized with an Mll 3 probe (Collins et al., 2000) (middle panel), or digested with HindIII and hybridized with an Enl 3 probe (left hand panel).
Ta  tail biopsy DNA; S  spleen DNA; L  liver DNA; K  kidney DNA; CL  an Mll-loxP; Enl-loxP; Cre cell line DNA; CCB  ES cell DNA
Markers were DNA cut with HindIII (Kb  kilobases).
B: Fluorescence in situ hybridization of cells from bone marrow (BM) or spleen cells of Mll-loxP; Enl-loxP or Mll-loxP; Enl-loxP; Cre mice using paints for
chromosome 9 (FITC) or chromosome 17 (Cy3). FISH analysis of BM from a Mll-loxP; Enl-loxP mouse or a leukemic mouse. The FISH analysis of cell lines
established from spleen cells of three independent tumors which arose in Mll-loxP; Enl-loxP; Cre mice. Representative metaphases are shown. White arrows
indicate the translocated chromosomes.
lated and recombination products were analyzed by genomic 21 mice was generated carrying the Mll-loxP and Enl-loxP alleles
PCR or RNA-based RT-PCR (Figure 1C). A genomic PCR prod- together with the Lmo2-Cre allele. Mice carrying the two loxP
uct, spanning the Mll-Enl chromosome t(9;17) junction, was alleles and the Cre allele (Mll-loxP; Enl-loxP; Cre) were compared
obtained which had the predicted sequence comprising chro- with mice carrying only the loxP alleles (Mll-loxP; Enl-loxP). By
mosome 9-loxP site-chromosome 17 (Figure 1D) and the cells 120 days, 100% of the Mll-loxP; Enl-loxP; Cre mice had died
were expressing a fusion mRNA, comprising Mll exon 10 fused or been sacrificed due to ill health, while all Mll-loxP; Enl-loxP
to Enl exon 2 (Figure 1E). These data confirm that the t(9;17) mice remained healthy (Figure 2A; a similar cohort of Lmo2-
Mll-Enl chromosomal translocation can occur in mouse cells Cre-only mice also remained disease free, data not shown).
and that the fusion mRNA is transcribed.
Post-mortem examination of Mll-loxP; Enl-loxP; Cre mice
showed splenomegaly, pale livers, kidneys, and bone marrows,Myeloid leukemias carrying t(9;17) develop Mll-Enl-Cre
but generally no macroscopic abnormality of thymus. Invasionin mice
of spleen was observed, with disruption of normal architectureThe possible tumorigenic effect of the Mll-Enl chromosomal
by leukemic cells (Figure 3 compares tissue histology of a normaltranslocation in mice was determined by studying mice in which
Mll-loxP; Enl-loxP mouse with a leukemic Mll-loxP; Enl-loxP;recombination between the Mll and Enl genes was mediated
Cre mouse). There was extensive infiltration of tumor leukocytesby Cre recombinase expressed from a knockin of Cre into the
hematopoietic regulator Lmo2 (unpublished data). A cohort of into peripheral organs such as liver and kidneys with prominent
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Figure 5. Chromosomal translocations can be detected in young asymptomatic mice
A 12-day-old litter from a cross between Mll-loxP; Enl-loxP homozygous mice and heterozygous Lmo2-Cre mice was used as a source of cells to examine
the occurrence of chromosomal translocations. Pups 2, 7, and 10 were analyzed in detail with fluorescence in situ hybridization and genomic PCR to
detect translocation products.
A: Bone marrow cells were maintained in temporary culture and metaphase spreads prepared for FISH with chromosome 9 and 17 paints. Metaphases
from pups 2, 7, and 10 were analyzed and representative hybridizations are shown. Mll-loxP; Enl-loxP; Cre pup 7 showed metaphases with reciprocal
chromosomal translocations (pup 7, left hand panel, representative of 90% of the spreads) or normal metaphases (pup 7, middle panel, 10% of spreads).
Mll-loxP; Enl-loxP; Cre pup 10 showed only normal metaphases (right hand panel). White arrows mark the position of the translocated chromosomes from
pup 7.
B: Genomic DNA was isolated from BM and spleen from pups 2, 7, and 10 and PCR carried out for 30 cycles with Lmo2-specific primers (left hand panel),
with Mll and Enl genomic primers (MG1  EG1) for 30 cycles (middle panel), or nested Mll and Enl genomic primers (MN  EN) for 30 cycles (right hand
panel) to give total of 60 cycles. Pup 2 was a Cre negative (Mll-loxP; Enl-loxP) while pups 7 and 10 were Mll-loxP; Enl-loxP; Cre mice.
-  no template control; BM  bone marrow; Spl  spleen; T  tumor from an Mll-loxP; Enl-loxP; Cre mouse; arrows indicate the PCR band corresponding
to the Lmo2 genomic product or the translocation junction product. White arrows indicate the translocated chromosomes.
C: Sequence of the BM chromosomal translocation product from a tumor.
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perivascular deposits of tumor cells in liver and in between Table 2. Modal distribution of chromosomes in metaphase spreads of cell
glomerili of kidney (Figure 3). lines from Mll-Enl-Cre mice
Blood smears showed large numbers of circulating myeloid Cell line No. metaphases No. chromosomes Modal number
cells (Figure 2B), with a mixture of immature myeloblasts and
1 18 37 (n  1) 39.8more mature myeloid forms. Microscopic analysis of the differ-
39 (n  3)
ent morphological cell types present in the leukemias is docu- 40 (n  12)
mented in Table 1. Ninety-five percent of the leukocytes are 41 (n  2)
2 18 39 (n  2) 40.0nonlymphoid cells, and of these, around 20% are immature
40 (n  14)cells/blasts and around 80% are mature myeloid cells, compris-
41 (n  2)ing around 60%–70% neutrophils, around 10% nonsegmented 3 19 36 (n  2) 39.7
forms, and 5% monocytic (Table 1). The surface antigen pheno- 40 (n  15)
41 (n  2)type of bone marrow, spleen, or thymus cells of tumor mice
showed that the Mll-loxP; Enl-loxP; Cre mice develop a leukemia Spleen cells were established in culture from tumour-bearing mice and
characterized by expression of the myeloid markers Mac-1 metaphase chromosomes prepared after treatment of the cells with col-
cemid. Chromosome spreads were made from fixed nuclei and spread on(CD11b) and Gr-1 (Ly-6G) (Figure 2C). Cell lines established from
glass slides for manual counting.spleens of leukemic mice also have a Mac-1; Gr-1 phenotype,
similar to those found on the primary biopsy material (Figure
2C). Neither the primary cells nor the cell lines express the
progenitor markers Sca-1 or c-Kit, nor do they express the
lymphoid markers CD4, CD8, or B220. The cells were initially The cloned PCR product from Mll-loxP; Enl-loxP; Cre mouse
grown in vitro in serum with added growth factors and subse- tumor cells confirmed the site-specific joining of Mll and Enl
quently grown without added growth factors. The myeloid mark- introns (Figure 5C), which was identical to that of the ES cell
ers are similar to cultured cells from leukemic Mll-AF9 knockin product and showed site-specific recombination between the
mice (Dobson et al., 1999) (Figure 2C). We conclude that the Mll- loxP sites.
loxP; Enl-loxP; Cre mice develop a leukemia involving myeloid A direct visualization of the reciprocal translocations was
lineage. All the Mll-loxP; Enl-loxP; Cre mice succumb to the obtained by fluorescence in situ hybridization (FISH) of tumor
myeloid neoplasm with aggressive infiltration of myeloid cells cell chromosomes from the Mll-loxP; Enl-loxP; Cre mice com-
into various organs. Overall, the morphological data, surface pared with Mll-loxP; Enl-loxP mice (Figure 4B). Short term bone
phenotype, and tissue involvement are most consistent with the marrow cultures were used for the preparation of metaphase
classification of the leukemia as “myeloproliferative-disease-like chromosomes. This revealed reciprocal chromosomal translo-
myeloid leukemia” according to mouse leukemia classification cations by hybridization with chromosome 9 and chromosome
(Kogan et al., 2002). 17 paints (Figure 4B). In addition, metaphases from Mll-loxP;
The leukemia observed in the Mll-Enl mice causes death in Enl-loxP; Cre tumor cell lines obtained from spleen cells also
all cases, unless the mouse was sacrificed due to obvious ill had reciprocal translocations t(9;17) and t(17;9) (Figure 4B). The
heath, and Mll-loxP; Enl-loxP; Cre mice all succumb in the first tumors from the Mll-loxP; Enl-loxP; Cre mice therefore carry
120 days after birth. The disease was only observed in individu- reciprocal chromosomal translocations. All the mice in the Mll-
als with both the loxP alleles and expressing Cre recombinase. loxP; Enl-loxP; Cre cohort were shown to have Mll-chromosomal
This suggested that the cause of leukemia was the generation translocations by either filter hybridization or by FISH analysis.
of cells in the individual mice with chromosomal translocations In addition, karyotypes associated with these de novo tumors
which outgrow and present as overt leukemia. The leukemic remained euploid, as at least the modal chromosome number
cells were not transplantable in nonirradiated recipients, al- of three independent cell lines, derived from leukemic mice,
though transplantation per se does not serve as a defining ele- were normal (i.e., 40 chromosomes; Table 2).
ment for mouse hematopoietic neoplasm (Kogan et al., 2002).
The presence of the reciprocal chromosomal translocations in Chromosomal translocations occur early in Mll-Enl mice
mice which succumbed to leukemia was confirmed by analysis The youngest Mll-loxP; Enl-loxP; Cre mouse to develop leuke-
of genomic DNA and by direct observation of translocated chro- mia was about 1.5 months of age. Thus, the onset of disease
mosomes. The presence of translocations in the leukemias was in these Mll-Enl translocator mice occurred very early in life and
shown using filter hybridization of DNA from tumor cells. DNA with a high penetrance, and was always associated with the
probes from 5 or 3 of the Mll gene breakpoint or from 3 of presence of the chromosomal translocations. Therefore, the
the Enl breakpoint were used to examine rearranged genomic chromosomal translocations events between Mll and Enl must
DNA restriction fragments (Figure 4A). This substantiated the occur early in the Mll-Enl-Cre mice to allow time for disease
presence of reciprocal translocations in the mice since the antic- manifestation. Possible timing and frequency of translocations
ipated restriction fragment products of translocations were were obtained using FISH on chromosomes from bone marrow
found. These were, specifically, a 7.0 Kb SphI fragment detected cells of young mice (12 days of age). Six Mll-loxP; Enl-loxP;
by the 5 Mll probe, a 9.5 Kb KpnI fragment detected by the 3 Cre pups from one litter (of 12) were analyzed. One showed
Mll probe, and a 3.0 Kb HindIII fragment detected by the 3 Enl translocations by FISH analysis in all metaphases examined
probe. Formal confirmation of the genomic breakpoint of the (Figure 5A, pup 7, 23 metaphases examined) while the other
translocation was obtained by genomic PCR of a product span- five pups had only normal chromosomes in 20-23 metaphases
ning relevant Mll and Enl introns, followed by DNA sequencing. examined (Figure 5A; a representative metaphase from pup 10).
The presence of the translocated Mll DNA fragment was con- Even though we obtained differential results with detection
of chromosomal translocations in the 12 day mice, the earlyfirmed in all the leukemic mice in the cohort (data not shown).
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onset of leukemia in the cohort (Figure 2) was suggestive of the intervention of further mutational events, as has been sug-
gested for human MLL translocations (Ford et al., 1993). A re-early and frequent interchromosomal translocations, followed
by selection of the cell(s) carrying the aberrant chromosomes. finement of this argument will depend on a detailed study of
candidate gene mutation and of genetic analysis for chromo-The sensitivity of the analysis for the 12 day pup 7 and pup
10 littermates was, therefore, extended using genomic PCR to somal instability. At present, we have examined the ploidy of
three cell lines obtained from the tumor-bearing mice, and thesedetect the junction of the chromosomal translocation t(9;17).
DNA was prepared from bone marrow (BM; Figure 5B) or spleen exhibit normal chromosome numbers (Table 2).
The Lmo2 gene is needed for the development of adultcells and splenic DNA from a leukemic mouse, and quality con-
trol was carried out using an Lmo2 gene primer pair. This yielded hematopoiesis (Yamada et al., 1998), and Cre expression from
the Lmo2-Cre knockin gene occurs in bone marrow (unpub-an Lmo2 product at 30 PCR cycles in all samples. When the
Mll-Enl chromosomal junction PCR was assessed at 30 cycles, lished data). The major site of the chromosomal translocation
is therefore likely to be bone marrow cells; this is supported bywe detected a product in the DNA of pup 7 bone marrow and
the tumor DNA but not in bone marrow DNA of pup 10 nor in the PCR and FISH analysis of 12-day-old mice (Figure 5) where
concentrations of cells with chromosomal translocations areeither pups 7 or 10 spleen DNA (Figure 5B, central panel). No
product was obtained with DNA from pup 2, which was Mll- high in bone marrow but not in spleen. The leukemia in this
model may initiate in bone marrow progenitors, which progressloxP; Enl-loxP only. The sequence of the tumor PCR product
was obtained to confirm the specific junctional information (Fig- and migrate to remote locations such as spleen, but this cannot
be proved in this de novo model. At the time of overt disease,ure 5C).
The presence of low concentrations of chromosomal trans- the abnormal myeloid cells are found to be invading somatic
tissues with typical, large perivascular deposits in liver andlocation-positive cells was assessed in these samples using
nested PCR, carried out for a further 30 PCR cycles. In this kidney.
analysis, we observed translocation-specific PCR products
from bone marrow DNA from pup 10 (pup 7 shows a product De novo chromosomal translocation mouse models
The de novo chromosomal translocations in mice are the closestat 30 cycles) and from spleen DNA of both pups 7 and 10 (Figure
5B), which did not amplify a product at 30 cycles. No product to natural, human chromosomal translocations of any model
thus far. The finding that interchromosomal translocations be-was obtained from the Cre-negative pup 2. These data therefore
show that Mll-Enl chromosomal translocations can occur in tween Mll and Enl in mice invariably lead to leukemia suggests
that the Cre-loxP in vivo approach (Buchholz et al., 2000; Collinsyoung mice, and that in some cases at least, it appears that
these arise initially in cells of bone marrow origin and subse- et al., 2000) can be employed, with appropriately specific Cre-
expressing mice, to any pair of genes as long as the orientationquently these cells migrate to spleen.
to the centromere does not result in dicentric aberrant chromo-
somes. The employment of cell-specific Cre expression or in-Discussion
ducible Cre will increase the versatility of this approach and
potentially make experiments possible which evaluate hierar-Early onset of Mll-Enl-associated leukemia
As in humans, the chromosomal translocation between mouse chies of genetic changes associated with human cancers with
chromosomal translocations. In addition, Cre-dependent, inter-Mll and Enl results in leukemia. The data from our study show
that mice with the compound genotype comprising loxP recom- chromosomal translocations result in leukemias with reciprocal
translocated chromosomes, which is a unique feature of thisbination sites with Mll and Enl genes develop leukemia only if
Cre recombinase is expressed. The Mll-Enl chromosomal trans- approach, and which may well be a crucial issue in cases where
the involvement of both translocated chromosomes has beenlocation thus always results in malignancy. The onset of malig-
nancy is rapid, which is consistent with retroviral transduction implicated (He et al., 1997).
The translocator mouse approach should not only providestudies (Ayton and Cleary, 2001; Lavau et al., 1997; Slany et
al., 1998), but in the translocator mice, the development of the basis for generating chromosomal translocations to mimic
the diversity of breakpoints in leukemias and sarcomas but, indisease occurs after a somatic event (i.e., chromosomal translo-
cation) and is not due to the simultaneous transplantation of addition, should provide an experimental framework for explor-
ing the role of translocations in epithelial tumors, where recurrentmany transduced, Mll-Enl-expressing cells. This implies that the
effect of Mll-Enl is paramount in the leukemic process, perhaps and non-recurrent translocations are found (Mitelman et al.,
2000). While tumors of epithelial cell origin do have chromo-the only event needed for leukemia. It is significant that young
mice with low number of cells with chromosomal translocations somal translocations (Dutrillaux, 1998), they do not appear to
fall into the recurrent category found in leukemias and sarcomas.(i.e., only detectable by nested PCR) coexist with littermates
Whether these arise due to genetic instability alone or whetherwith high numbers of chromosomal translocation-positive cells.
they have, in addition, pathogenic consequences for the individ-This must reflect the time at which the interchromosomal event
ual tumors (idiopathic) is not known. The ability to make deoccurred (these are not a constitutional chromosomal transloca-
novo translocations to recapitulate idiopathic chromosomaltion, and we can define neither the timing in individual mice
translocations should be an invaluable tool to ascertain thenor how long overt disease takes to manifest itself after the
significance of these aberrant chromosomes in cancer.chromosomal translocation event) and the putative selectivity
which is conferred on the cell that undergoes chromosomal
Experimental procedurestranslocation. The early appearance of large proportions of
translocation carrying cells (i.e., as early as 12 days) further Gene targeting and production of translocator mice
could suggest that the emergence of overt hematopoietic malig- The mouse Mll genomic fragment with exon 10 and loxP has been previously
described (Collins et al., 2000). Genomic  phage DNA clones of the mousenancy is wholly dependent on the Mll-Enl fusion gene, without
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Enl gene were isolated from a library of 129 DNA using a human cDNA clone in fixative (3:1 ethanol: glacial acetic acid), resuspended in fixative, and
dropped onto glass slides. After denaturation with 70% formamide, meta-made by PCR amplifying a 350 bp fragment including exon 2. The loxP-
hygromycin and puromycin-loxP cassettes (Collins et al., 2000) were cloned phase spreads were hybridized with FITC-labeled chromosome 9 paint and
Cy3-labeled chromosome 17 paint for 16 hr at 42C. After two stringentinto BglII (Collins et al., 2000) and SphI sites of Mll and Enl, respectively,
to generate the two targeting vectors pMll-loxP-hygro and pEnl-loxp-puro washes with 50% formamide, spreads were mounted with DAPI (Vector
Laboratories, Burlingame, California) and analyzed at 1000 magnification(Figures 1A and 1B). Homologous recombination was carried out into CCB
ES cells as described (Robertson, 1987) using either hygromycin- or puromy- under oil immersion. Image analysis was performed with Smart Capture 2.1
(Digital Scientific, Cambridge, United Kingdom). Bone marrow and spleencin-resistant mouse embryonic fibroblast feeders as appropriate (Johnson
single cell suspensions were short-term cultured, as for tumor cells for 2–5et al., 1995; Linnell et al., 2001). Targeted ES clones were identified by filter
days prior to FISH analysis.hybridization (LeFranc et al., 1986) using 5 and 3 flanking probes from Mll
genomic DNA (Figure 1A). The 5 Enl flanking probe was a 1 kb BamHI 
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This work was funded by the Medical Research Council. M.M. was supportedwith the pEnl-loxP-puro clone to make double-targeted ES clones. To deter-
by a grant from the Leukemia Research Fund and E.C. was the recipient ofmine if interchromosomal translocation between Mll and Enl could occur,
a Leukemia Research Fund Gordon Pillar Studentship. We would like todouble-targeted clones were transiently transfected with the Cre recombi-
thank Drs. Alan Warren and Tobias Menne for detailed analysis of blood cellnase expression vector pPGKCrebpA using electroporation (Collins et al.,
morphologies and Angela Middleton and Gareth King for assistance with2000). After 72 hr, cells were harvested, RNA was prepared using Trizol
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